Instillation of Mitomycin C and Doxorubicin in the Prevention of Recurrent Superficial (Ta—T1) Bladder Cancer
- 1 July 1987
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 60 (1) , 54-59
- https://doi.org/10.1111/j.1464-410x.1987.tb09134.x
Abstract
Both Mitomycin C (MMC) and doxorubicin (Adriamycin) (ADM) prevent the recurrence of superficial papillary (Ta-T1) urinary bladder cancers and also reduce the rate of progression. MMC appears to be more effective than ADM in buffered instillations. The number of recurrent tumours (RI/m) and the number of recurrence times (RR) before prophylactic instillation were of significant prognostic importance but the prognostic value of the grade was questionable. The buffer solution, together with methyl prednisolone, reduced the incidence of chemical cystitis.This publication has 23 references indexed in Scilit:
- Detecting mitomycin C in human plasma during intravesical therapyInternational Urology and Nephrology, 1985
- Welche oberflächlichen Übergangszellkarzinome der Harnblase sollten adjuvant chemotherapeutisch behandelt werden?Aktuelle Urologie, 1985
- Intravesical doxorubicin for the prophylaxis of superficial bladder tumors. A multicenter studyCancer, 1984
- A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder CancerBritish Journal of Urology, 1983
- Therapy of Bladder CarcinomaScandinavian Journal of Urology and Nephrology, 1981
- TNM (1978) in Bladder Cancer: Use and AbuseBritish Journal of Urology, 1980
- Analysis of bladder tumor recurrence in 178 patientsUrology, 1980
- Intracavitary Epodyl® for Multiple, Non-Invasive, Highly Differentiated Bladder TumoursScandinavian Journal of Urology and Nephrology, 1980
- Optimal Intravesical Dosage of Thio-Tepa in the Prophylaxis of Recurrent Bladder PapillomatosisScandinavian Journal of Urology and Nephrology, 1972